Current view of treatment of localized prostate cancer in elderly men
Abstract
The approaches to the treatment of prostate cancer (PCa) has changed considerably over the last decade. Currently, prostate cancer is one of the most common malignancy and the second leading cause of death among men. The incidence of this disease increases with age, that is why doctors are increasingly facing problems with prostate cancer treatment in older patients. In numerous studies it was shown that carefully selected prostate cancer treatment provides similar survival results of elderly and younger patients. However, in older patients overall health and related diseases can adversely affect the efficacy and safety of different treatment methods. Furthermore, the heterogeneity of the patients population requires a multidisciplinary approach to select proper treatment modality (active surveillance or maintenance therapy) and to determine the use of the conservative and (or) surgical treatment of prostate cancer.
References
1. Alekseev B. Ya. The combined cancer therapy of a prostate gland / / Onkourologiya. - 2012. - No. 4. - Page 77-82. Russian (Алексеев Б. Я. Комбинированное лечение рака предстательной железы // Онкоурология. - 2012. - № 4. - С. 77-82).
2. Siegel R., Naishadham D., Jemal A. Cancer statistics // CA Cancer J. Clin. - 2013. - Vol. 63, № 1. - Р. 11-30.
3. Chissov V. I., Rusakov I. G. Cancer cases of a prostate gland in the Russian Fed-eration//Experimental and clinical urology. - 2011. - No. 2-3. - Page 6-7. Russian (Чиссов В. И., Русаков И. Г. Заболеваемость раком предстательной железы в Российской федерации // Экспериментальная и клиническая урология. - 2011. - № 2-3. - С. 6-7).
4. Fung C. Dale W., Mohile S. Prostate cancer in the elderly patient // J. Clin. Oncol. - 2014. - Vol. 32, № 24. - Р. 2523-2530.
5. Zlotta A. R., Egawa S., Pushkar D. et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men // J. Natl Cancer Inst. - 2013. - Vol. 105, № 14. - Р. 1050-1058.
6. Schroder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized European study // N. Eng.l J. Med. - 2009. - Vol. 360, № 13. - Р. 1320-1328.
7. Dale W., Mohile S. G., Eldadah B.A. et al. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research // J. Natl Cancer Inst. - 2012. - Vol. 104, № 8. - Р. 581-589.
8. Sajid S., Mohile S. G., Szmulewitz R. et al. Individualized decision-making for older men with prostate cancer: Balancing cancer control with treatment consequences across the clinical spectrum // Semin. Oncol. - 2011. - Vol. 38, № 2. - Р. 309-325.
9. Dale W. “Staging the aging” when considering androgen deprivation therapy for older men with prostate cancer // J. Clin. Oncol. - 2009. - Vol. 27, № 21. - Р. 3420-3422.
10. Scosyrev E., Messing E. M., Mohile S. et al. Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality // Cancer. - 2012. - Vol. 118, № 12. - Р. 3062-3070.
11. Larina V. N., Raspopova T. N. The mineral density of a bone tissue and bone exchange at chronic heart failure. Cardiology of 2016: 7: 39-46 (Ларина В. Н., Распопова Т. Н. Минеральная плотность костной ткани и костный обмен при хронической сердечной недостаточности. Кардиология 2016: 7: 39-46. Russian).
12. Koroukian S. M., Murray P., Madigan E. Comorbidity, disability, and geriatric syndromes in elderly cancer patients receiving home health care // J. Clin. Oncol. - 2006. - Vol. 24, № 15. - Р. 2304-2310.
13. Mohile S., Dale W., Hurria A. Geriatric oncology research to improve clinical care // Nat. Rev. Clin. Oncol. - 2012. - Vol. 9, № 10. - Р. 571-578.
14. Hurria A., Cohen H.J., Extermann M. Geriatric Oncology Research in the Cooperative Groups: A Report of a SIOG Special Meeting // J. Geriatr Oncol. - 2010. - Vol. 1, № 1. - Р. 40-44.
15. Mohile S. G., Bylow K., Dale W. et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation // Cancer. - 2007. - Vol. 109, № 4. - Р. 802-810.
16. Hurria A., Togawa K., Mohile S. G. et al. Predicting chemotherapy toxicity in older adults with cancer: а prospective multicenter study // J. Clin. Oncol. - 2011. - Vol. 29, № 25. - Р. 3457-3465.
17. Ketelaars L., Pottel L., Lycke M. et al. Use of the Freund clock drawing test within the Mini-Cog as a screening tool for cognitive impairment in elderly patients with or without cancer // J. Geriatr. Oncol. - 2013. - Vol. 4, № 2. - Р. 174-182.
18. Mohile S. G., Xian Y., Dale W. et al. Association of a cancer diagnosis with vulnerability and frailty inolder Medicare beneficiaries // J. Natl Cancer Inst. - 2009. - Vol. 101, № 17. - Р. 1206-1215.
19. D’Amico A. V., Moul J., Carroll P. R. et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era // J. Clin. Oncol. - 2003. - Vol. 21, № 11. - Р. 2163-2172.
20. Fleming C., Wasson J. H., Albertsen P. C. et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer: Prostate Patient Outcomes Research Team // JAMA. - 1993. - Vol. 269, № 20. - Р. 2650-2658.
21. Droz J. P., Balducci L., Bolla M. et al. Management of prostate cancer in older men: Recommendations of a working group of the International Society of Geriatric Oncology // BJU Int. - 2010. - Vol. 106, № 4. - Р. 462-469.
22. Bill-Axelson A., Holmberg L., File'n F. et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial // J. Natl Cancer Inst. - 2008. - Vol. 100, № 16. - Р. 1144-1154.
23. Wilt T. J., Brawer M. K., Jones K. M. et al. Radical prostatectomy versus observation for localized prostate cancer // N. Eng.l J. Med. - 2012. - Vol. 367, № 3. - Р. 203-213.
24. Aizer A. A., Paly J. J., Zietman A. L. et al. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J. Clin. Oncol. 2012; 30 (25): 3071-3076.
25. Stephenson A. J., Kattan M. W., Eastham J. A. et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era // J. Clin. Oncol. - 2009. - Vol. 27, № 26. - Р. 4300-4305.
26. Alibhai S. M., Naglie G., Nam R. et al. Do older men benefit from curative therapy of localized prostate cancer? // J. Clin. Oncol. - 2003. - Vol. 21, № 17. - Р. 3318-3327.
27. Walsh P. C., DeWeese T. L., Eisenberger M. A. Clinical practice. Localized prostate cancer // N. Engl. J. Med. - 2007. - Vol. 357, № 26. - Р. 2696-2705.
28. Begg C. B., Riedel E. R., Bach P. B. Variations in morbidity after radical prostatectomy // N. Engl. J. Med. - 2002. - Vol. 346, № 15. - Р. 1138-1144.
29. Siddiqui S. A., Sengupta S., Slezak J. M. et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer // J. Urol. - 2006. - Vol. 175, № 3. - Р. 952-957.
30. Resnick M. J., Koyama T., Fan K. H. et al. Long-term functional outcomes after treatment for localized prostate cancer // N. Engl. J. Med. - 2013. - Vol. 368, № 5. - Р. 436-445.
31. Poushkar D. Yu., Yudovsky S. O. Correction of erectile dysfunction at the patients who have transferred a radical prostatektomiya // Urology. - 2014. - No. 2. - P. 68-71. Russian (Пушкарь Д. Ю., Юдовский С. О. Коррекция эректильной дисфункции у пациентов, перенесших радикальную простатэктомию // Урология. - 2014. - № 2. - С. 68-71).
32. Bolla M., de Reijke T. M., Van Tienhoven G. et al. Duration of androgen suppression in the treatment of prostate cancer // N. Engl. J. Med. - 2009. - Vol. 360, № 24. - Р. 2516-2527.
33. D’Amico A. V., Chen M. H., Renshaw A. A. et al. Androgen suppression and radiation vs radiation alone for prostate cancer: а randomized trial // JAMA. - 2008. - Vol. 299, № 3. - Р. 289-295.
34. Jones C., Hunt D., McGowan D. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer // N. Engl. J. Med. - 2011. - Vol. 365, № 2. - Р. 107-118.
35. Nanda A., Chen M. H., Moran B. J. et al. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy // Int. J. Radiat. Oncol. Biol. Phys. - 2013. - Vol. 85, № 5. - Р. 209-215.
36. Studer U. E., Whelan P., Wimpissinger F. et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC Randomized Trial 30891 with 12 years of follow-up // Eur. Urol. - 2014. - Vol. 66, № 5. - Р. 829-838.
37. Johansson E., Steineck G., Holmberg L. et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial // Lancet Oncol. - 2011. - Vol. 12, № 9. - Р. 891-899.
Review
For citations:
Dariy E.V. Current view of treatment of localized prostate cancer in elderly men. Medical alphabet. 2017;1(16):36-41. (In Russ.)
Views:
244
Email this article 